Secondary analysis of EPIC-CAD (AF plus stable CAD; 421 of 1040 with diabetes): edoxaban alone vs edoxaban plus an antiplatelet lowered the 12-month composite of death, ischaemic events and bleeding in diabetics (6.3% vs 13.7%; HR 0.44) and non-diabetics alike.
Secondary analysisn = 1,040
Lee et al. Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial